CA
BMY icon

Calton & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Calton & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
+5,244
New +$301K 0.04% 312
2026
Q1 		– Sell
-6,716
Closed -$362K – 446
2025
Q4 		$362K Buy
+6,716
New +$323K 0.05% 289
2024
Q4 		– Sell
-15,503
Closed -$802K – 199
2024
Q3 		$802K Buy
15,503
+5,711
+58% +$268K 0.31% 77
2024
Q2 		$407K Sell
9,792
-994
-9% -$44.5K 0.2% 108
2024
Q1 		$585K Buy
+10,786
New +$549K 0.29% 83
2023
Q1 		– Sell
-2,865
Closed -$206K – 243
2022
Q4 		$206K Buy
+2,865
New +$216K 0.08% 257
2022
Q1 		– Sell
-4,145
Closed -$258K – 361
2021
Q4 		$258K Sell
4,145
-1,882
-31% -$110K 0.07% 298
2021
Q3 		$356K Sell
6,027
-551
-8% -$36.3K 0.08% 253
2021
Q2 		$439K Buy
6,578
+96
+1% +$6.26K 0.08% 218
2021
Q1 		$409K Sell
6,482
-1,989
-23% -$124K 0.08% 223
2020
Q4 		$525K Sell
8,471
-1,743
-17% -$107K 0.09% 174
2020
Q3 		$616K Sell
10,214
-1,249
-11% -$75.2K 0.13% 136
2020
Q2 		$674K Buy
11,463
+756
+7% +$45.2K 0.15% 114
2020
Q1 		$597K Sell
10,707
-2,225
-17% -$136K 0.15% 123
2019
Q4 		$830K Buy
12,932
+4,923
+61% +$282K 0.17% 116
2019
Q3 		$406K Sell
8,009
-550
-6% -$25.8K 0.09% 184
2019
Q2 		$388K Buy
8,559
+68
+0.8% +$3.17K 0.11% 158
2019
Q1 		$405K Sell
8,491
-1,180
-12% -$58.8K 0.12% 152
2018
Q4 		$503K Buy
9,671
+1,224
+14% +$65.8K 0.19% 109
2018
Q3 		$524K Sell
8,447
-2,733
-24% -$162K 0.15% 114
2018
Q2 		$673K Sell
11,180
-6,331
-36% -$342K 0.2% 88
2018
Q1 		$1.11M Buy
17,511
+967
+6% +$62.2K 0.32% 62
2017
Q4 		$1.05M Buy
+16,544
New +$1.03M 0.26% 67

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Calton & Associates's BMY Position: Q2 2026 in Review

Calton & Associates opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 5,244 shares worth $302K. The stake represents 0.04% of the portfolio and ranks #312 among its holdings. This is a return to the name: Calton & Associates previously reported a position in BMY as recently as Q4 2025.

Calton & Associates first reported a position in BMY in Q4 2017 and has held it in 23 quarters since. The position peaked at $1.11M in Q1 2018. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Calton & Associates held 5,244 shares of Bristol-Myers Squibb worth $302K as of Q2 2026.
  • Bristol-Myers Squibb was a new Calton & Associates position in Q2 2026.
  • Bristol-Myers Squibb made up 0.04% of Calton & Associates's portfolio in Q2 2026, its #312 holding.
  • Calton & Associates first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 23 quarters since.
  • Calton & Associates's Bristol-Myers Squibb position peaked at $1.11M in Q1 2018.
  • 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.